A randomized, double-blind, phase III clinical trial (NCT02849496) demonstrated that adding olaparib to neoadjuvant or adjuvant chemotherapy significantly improved IDFS in patients with early-stage HER2- breast cancer who also had a BRCA1 or BRCA2 mutation. Here, BRCA1 is linked to breast carcinoma.